Predicting hidden cancer spread in gastric cancer patients
A Nomogram for Predicting Occult Omental Metastasis in Patients With Gastric Cancer
This study looks at gastric cancer patients to see how often and why cancer spreads to the omentum after they have surgery to remove their stomach.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Northern Jiangsu People's Hospital Academic / other |
| Locations | 1 site (Yangzhou, Jiangsu) |
| Trial ID | NCT06405009 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the frequency and risk factors associated with omental metastasis in patients diagnosed with gastric cancer who are undergoing total gastrectomy. It involves a prospective cohort of patients who will have their omentum examined separately for pathological assessment after surgery. The study will categorize patients based on postoperative pathology to analyze their characteristics and risk factors related to metastasis. The primary outcome will focus on the detection of any metastases in the greater omentum.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a confirmed diagnosis of gastric cancer who are eligible for surgical intervention.
Not a fit: Patients with multiple primary malignancies or severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve surgical decision-making and patient outcomes by identifying patients at higher risk for omental metastasis.
How similar studies have performed: While similar studies have explored metastasis in gastric cancer, this specific predictive model for omental metastasis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. pathological confirmation of gastric cancer 2. eligibility for surgical intervention 3. undergoing first rectal cancer surgery 4. acquisition of written informed consent from patients and their families 5. no history of hypertrophic scar or allergic predispositions Exclusion Criteria: 1. absence of postoperative pathology of the omentum 2. diagnosis of multiple primary malignancies 3. intraoperative discovery of widespread implant metastases within the abdominal cavity 4. severe comorbidities
Where this trial is running
Yangzhou, Jiangsu
- Yifan Cheng — Yangzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Yifan Cheng
- Email: cyfchengyifan528@sina.com
- Phone: 8615267258283
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.